Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 114

1.

Criteria for symptom remission revisited: a study of patients affected by schizophrenia and schizoaffective disorders.

Pinna F, Tusconi M, Bosia M, Cavallaro R, Carpiniello B; Cagliari Recovery Group Study.

BMC Psychiatry. 2013 Sep 26;13:235. doi: 10.1186/1471-244X-13-235.

PMID:
24294839
[PubMed - indexed for MEDLINE]
Free PMC Article
2.

Establishing remission and good clinical functioning in schizophrenia: predictors of best outcome with long-term risperidone long-acting injectable treatment.

Lambert M, De Marinis T, Pfeil J, Naber D, Schreiner A.

Eur Psychiatry. 2010 May;25(4):220-9. doi: 10.1016/j.eurpsy.2009.09.001. Epub 2009 Nov 18.

PMID:
19926263
[PubMed - indexed for MEDLINE]
3.

Patient-based and clinician-based support for the remission criteria in schizophrenia.

Docherty JP, Bossie CA, Lachaux B, Bouhours P, Zhu Y, Lasser R, Gharabawi GM.

Int Clin Psychopharmacol. 2007 Jan;22(1):51-5.

PMID:
17159460
[PubMed - indexed for MEDLINE]
4.

Item response analysis of the Positive and Negative Syndrome Scale.

Santor DA, Ascher-Svanum H, Lindenmayer JP, Obenchain RL.

BMC Psychiatry. 2007 Nov 15;7:66.

PMID:
18005449
[PubMed - indexed for MEDLINE]
Free PMC Article
5.

Symptomatic remission and cognitive impairment in first-episode schizophrenia: a prospective 3-year follow-up study.

Chang WC, Ming Hui CL, Yan Wong GH, Wa Chan SK, Ming Lee EH, Hai Chen EY.

J Clin Psychiatry. 2013 Nov;74(11):e1046-53. doi: 10.4088/JCP.13m08355.

PMID:
24330905
[PubMed - indexed for MEDLINE]
6.

Defining and predicting functional outcome in schizophrenia and schizophrenia spectrum disorders.

Schennach-Wolff R, Jäger M, Seemüller F, Obermeier M, Messer T, Laux G, Pfeiffer H, Naber D, Schmidt LG, Gaebel W, Huff W, Heuser I, Maier W, Lemke MR, Rüther E, Buchkremer G, Gastpar M, Möller HJ, Riedel M.

Schizophr Res. 2009 Sep;113(2-3):210-7. doi: 10.1016/j.schres.2009.05.032. Epub 2009 Jun 27.

PMID:
19560901
[PubMed - indexed for MEDLINE]
7.

The Brief Adherence Rating Scale (BARS) validated against electronic monitoring in assessing the antipsychotic medication adherence of outpatients with schizophrenia and schizoaffective disorder.

Byerly MJ, Nakonezny PA, Rush AJ.

Schizophr Res. 2008 Mar;100(1-3):60-9. doi: 10.1016/j.schres.2007.12.470. Epub 2008 Feb 5.

PMID:
18255269
[PubMed - indexed for MEDLINE]
8.

Efficacy and tolerability of ziprasidone versus risperidone in patients with acute exacerbation of schizophrenia or schizoaffective disorder: an 8-week, double-blind, multicenter trial.

Addington DE, Pantelis C, Dineen M, Benattia I, Romano SJ.

J Clin Psychiatry. 2004 Dec;65(12):1624-33.

PMID:
15641867
[PubMed - indexed for MEDLINE]
9.

Remission in prognosis of functional outcome: a new dimension in the treatment of patients with psychotic disorders.

Helldin L, Kane JM, Karilampi U, Norlander T, Archer T.

Schizophr Res. 2007 Jul;93(1-3):160-8. Epub 2007 Mar 28.

PMID:
17395430
[PubMed - indexed for MEDLINE]
10.

One-year functional outcomes of naturalistically treated patients with schizophrenia.

Spellmann I, Riedel M, Schennach R, Seemüller F, Obermeier M, Musil R, Jäger M, Schmauß M, Laux G, Pfeiffer H, Naber D, Schmidt LG, Gaebel W, Klosterkötter J, Heuser I, Maier W, Lemke MR, Rüther E, Klingberg S, Gastpar M, Möller HJ.

Psychiatry Res. 2012 Aug 15;198(3):378-85. doi: 10.1016/j.psychres.2011.12.047. Epub 2012 Mar 14.

PMID:
22421065
[PubMed - indexed for MEDLINE]
11.

Remission in schizophrenia: Results from a 1-year study of long-acting risperidone injection.

Lasser RA, Bossie CA, Gharabawi GM, Kane JM.

Schizophr Res. 2005 Sep 15;77(2-3):215-27.

PMID:
15908183
[PubMed - indexed for MEDLINE]
12.

Efficacy and safety of aripiprazole and haloperidol versus placebo in patients with schizophrenia and schizoaffective disorder.

Kane JM, Carson WH, Saha AR, McQuade RD, Ingenito GG, Zimbroff DL, Ali MW.

J Clin Psychiatry. 2002 Sep;63(9):763-71.

PMID:
12363115
[PubMed - indexed for MEDLINE]
13.

Efficacy of iloperidone in the short-term treatment of schizophrenia: a post hoc analysis of pooled patient data from four phase III, placebo- and active-controlled trials.

Citrome L, Meng X, Hochfeld M, Stahl SM.

Hum Psychopharmacol. 2012 Jan;27(1):24-32. doi: 10.1002/hup.1254. Epub 2011 Dec 7.

PMID:
22161738
[PubMed - indexed for MEDLINE]
14.

Remitted but still impaired? Symptomatic versus functional remission in patients with schizophrenia.

Karow A, Moritz S, Lambert M, Schöttle D, Naber D; EGOFORS Initiative.

Eur Psychiatry. 2012 Aug;27(6):401-5. doi: 10.1016/j.eurpsy.2011.01.012. Epub 2011 May 12.

PMID:
21570262
[PubMed - indexed for MEDLINE]
15.

Responses to antipsychotic therapy among patients with schizophrenia or schizoaffective disorder and either predominant or prominent negative symptoms.

Stauffer VL, Song G, Kinon BJ, Ascher-Svanum H, Chen L, Feldman PD, Conley RR.

Schizophr Res. 2012 Feb;134(2-3):195-201. doi: 10.1016/j.schres.2011.09.028. Epub 2011 Oct 21.

PMID:
22019076
[PubMed - indexed for MEDLINE]
16.

Quality of life and subjective well-being in schizophrenia and schizophrenia spectrum disorders: valid predictors of symptomatic response and remission?

Schennach-Wolff R, Jäger M, Obermeier M, Schmauss M, Laux G, Pfeiffer H, Naber D, Schmidt LG, Gaebel W, Klosterkötter J, Heuser I, Kühn KU, Lemke MR, Rüther E, Klingberg S, Gastpar M, Seemüller F, Möller HJ, Riedel M.

World J Biol Psychiatry. 2010 Aug;11(5):729-38. doi: 10.3109/15622971003690289.

PMID:
20380620
[PubMed - indexed for MEDLINE]
17.

Olanzapine in refractory schizophrenia after failure of typical or atypical antipsychotic treatment: an open-label switch study.

Lindenmayer JP, Czobor P, Volavka J, Lieberman JA, Citrome L, Sheitman B, Chakos M, McEvoy JP.

J Clin Psychiatry. 2002 Oct;63(10):931-5.

PMID:
12416603
[PubMed - indexed for MEDLINE]
18.

Remission and recovery during the first outpatient year of the early course of schizophrenia.

Ventura J, Subotnik KL, Guzik LH, Hellemann GS, Gitlin MJ, Wood RC, Nuechterlein KH.

Schizophr Res. 2011 Oct;132(1):18-23. doi: 10.1016/j.schres.2011.06.025. Epub 2011 Jul 18.

PMID:
21764563
[PubMed - indexed for MEDLINE]
Free PMC Article
19.

The retinoid X receptor agonist bexarotene relieves positive symptoms of schizophrenia: a 6-week, randomized, double-blind, placebo-controlled multicenter trial.

Lerner V, Miodownik C, Gibel A, Sirota P, Bush I, Elliot H, Benatov R, Ritsner MS.

J Clin Psychiatry. 2013 Dec;74(12):1224-32. doi: 10.4088/JCP.12m08160.

PMID:
24434091
[PubMed - indexed for MEDLINE]
20.

The influence of the CYP2D6 polymorphism on psychopathological and extrapyramidal symptoms in the patients on long-term antipsychotic treatment.

Plesnicar BK, Zalar B, Breskvar K, Dolzan V.

J Psychopharmacol. 2006 Nov;20(6):829-33. Epub 2006 Feb 14.

PMID:
16478753
[PubMed - indexed for MEDLINE]
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk